UCB PHARMA SA
🇧🇪Belgium
- Country
- 🇧🇪Belgium
- Ownership
- Public, Subsidiary
- Established
- 1928-01-01
- Employees
- 9K
- Market Cap
- $34.9B
A Trial to Assess the Efficacy and Safety of SPM 927 (Lacosamide) in Subjects With Painful Distal Diabetic Neuropathy
Phase 3
Completed
- Conditions
- Diabetic Neuropathy
- First Posted Date
- 2005-10-13
- Last Posted Date
- 2014-09-22
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 357
- Registration Number
- NCT00238524
- Locations
- 🇩🇪
Schwarz, Monheim, Germany
An Open-label Continuation Trial to Assess the Continued Efficacy and Safety of Ascending Doses of Lacosamide in Subjects With Chronic Refractory Neuropathic Pain
- First Posted Date
- 2005-10-12
- Last Posted Date
- 2017-08-28
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 7
- Registration Number
- NCT00237458
A Follow-On Trial to Assess the Long Term Safety and Efficacy of SPM 927 in Painful Distal Diabetic Neuropathy
- First Posted Date
- 2005-10-10
- Last Posted Date
- 2018-07-17
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 451
- Registration Number
- NCT00235443
A Trial to Assess the Efficacy and Safety of SPM 927 in Subjects With Painful Distal Diabetic Neuropathy
Phase 2
Completed
- Conditions
- Diabetic Neuropathy
- First Posted Date
- 2005-10-10
- Last Posted Date
- 2014-09-22
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 496
- Registration Number
- NCT00235469
- Locations
- 🇺🇸
Schwarz, RTP, North Carolina, United States
A Trial to Assess the Long-term Safety and Efficacy of Lacosamide in Subjects With Painful Diabetic Neuropathy
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2023-07-24
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 371
- Registration Number
- NCT00220337
A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Trial to Investigate the Efficacy and Safety of SPM 927 (200mg/Day and 400mg/Day) as Adjunctive Therapy in Subjects With Partial Seizures With or Without Secondary Generalization
Phase 3
Completed
- Conditions
- Partial Seizures With or Without Secondary Generalization
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2014-09-22
- Lead Sponsor
- UCB Pharma
- Registration Number
- NCT00220415
- Locations
- 🇩🇪
Schwarz, Monheim, Germany
Levetiracetam Versus Standard Antiepileptic Drugs (Carbamazepine and Valproate) Used as Monotherapy in Patients With Newly Diagnosed Epilepsy
Phase 3
Completed
- Conditions
- Epilepsy
- Interventions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2015-03-17
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 1701
- Registration Number
- NCT00175903
Levetiracetam in the Treatment of Neuroleptic-induced Tardive Dyskinesia
Phase 2
Completed
- Conditions
- Dyskinesia, Medication-induced
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2013-12-06
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 70
- Registration Number
- NCT00175955
A Placebo-controlled Study of Levetiracetam In Children (1mo to 4yrs of Age) With Partial Onset Seizures.
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2020-10-01
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 116
- Registration Number
- NCT00175890
Open Label Study (Everyone Who Participates Receives Drug) to Further Determine How Safe and Effective Oral Treatment of Seletracetam is in Patients With Refractory Epilepsy.
Phase 3
Withdrawn
- Conditions
- Epilepsy
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2012-03-20
- Lead Sponsor
- UCB Pharma
- Registration Number
- NCT00175864
© Copyright 2025. All Rights Reserved by MedPath